Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Fabio Canino
Observed names:
Canino, F.,
Canino, Fabio,
F. Canino
Institutions:
University of Modena and Reggio Emilia,
Azienda Ospedaliero-Universitaria di Modena
Observed institutions:
University of Modena and Reggio Emilia,
University of Parma,
Italian Oncology Group of Clinical Research,
Azienda Ospedaliero-Universitaria di Modena
ORCID:
0000-0002-1379-7667
Observed ORCID:
0000-0002-1379-7667
OpenAlex ID:
A5005314643
Targeting PI3K/AKT/mTOR Pathway in Breast Cancer: From Biology to Clinical Challenges
2023
·
Krisida Cerma
, Federico Piacentini
, et al.
·
Biomedicines
·
115
PDF
Ocular Toxicity in Breast Cancer Management: Manual for The Oncologist
2022
·
Fabio Canino
, Claudia Omarini
, et al.
·
Clinical Breast Cancer
·
22
Safety and efficacy analysis of neoadjuvant pertuzumab, trastuzumab and standard chemotherapy for HER2–positive early breast cancer: real–world data from NeoPowER study
2024
·
Fabio Canino
, Monica Barbolini
, et al.
·
BMC Cancer
·
13
Role of Intrinsic Subtype Analysis with PAM50 in Hormone Receptors Positive HER2 Negative Metastatic Breast Cancer: A Systematic Review
2022
·
Fabio Canino
, Federico Piacentini
, et al.
·
International Journal of Molecular Sciences
·
13
PDF
T-DM1 efficacy in trastuzumab-pertuzumab pre-treated HER2 positive metastatic breast cancer patients: a meta-analysis
2022
·
Claudia Omarini
, Federico Piacentini
, et al.
·
BMC Cancer
·
13
PDF
The Prognostic Role of Early Skeletal Muscle Mass Depletion in Multimodality Management of Patients with Advanced Gastric Cancer Treated with First Line Chemotherapy: A Pilot Experience from Modena Cancer Center
2021
·
Margherita Rimini
, Annarita Pecchi
, et al.
·
Journal of Clinical Medicine
·
12
PDF
Incorporating weekly carboplatin in anthracycline and paclitaxel-containing neoadjuvant chemotherapy for triple-negative breast cancer: propensity-score matching analysis and TIL evaluation
2022
·
Maria Vittoria Dieci
, Luisa Carbognin
, et al.
·
British Journal of Cancer
·
10
PDF
Real-World Data and Clinical Implications of Next-Generation Sequencing (NGS)-Based Analysis in Metastatic Breast Cancer Patients
2024
·
Fabio Canino
, Antonio Tornincasa
, et al.
·
International Journal of Molecular Sciences
·
9
PDF
Update on Pulmonary Toxicity Induced by New Breast Cancer Treatments
2025
·
Lorenzo Belluzzi
, Giulio Martinelli
, et al.
·
Breast Cancer Targets and Therapy
·
5
PDF
Cemiplimab- and nivolumab-induced myasthenia gravis: two clinical cases
2021
·
Fabio Canino
, Giuseppe Pugliese
, et al.
·
Tumori Journal
·
4
Role of Pectoralis Muscle Analysis in Breast Magnetic Resonance Imaging for Body Composition Evaluation Before and After Neoadjuvant Chemotherapy for Breast Cancer
2025
·
Annarita Pecchi
, Francesca Mogavero
, et al.
·
Nutrients
·
3
PDF
Time to next treatment to evaluate the therapeutic sequence after first- or second-line CDK4/6 inhibitors of hormone receptor-positive, HER2-negative advanced breast cancer in Italy: a retrospective/prospective observational trial GOIRC-04-2019
2025
·
L. Moscetti
, E. Barbieri
, et al.
·
ESMO Real World Data and Digital Oncology
·
2
PDF
Abstract PO1-05-02: CDK4/6 inhibitors in advanced breast cancer (aBC). Preliminary results of the CDK4/6i choice and sequence of treatments in a series of 174 patients. GOIRC-04-2019 retro/prospective observational study
2024
·
Luca Moscetti
, Fabio Canino
, et al.
·
Cancer Research
·
2
Thromboembolism and Adjuvant Endocrine Therapy (AET) in Hormone Receptor-Positive Early Breast Cancer (EBC): Did Treatment Evolution Change Incidence of the Adverse Event? A Meta-Analysis
2023
·
Raffaella D'Onofrio
, Isabella Sperduti
, et al.
·
Clinical Breast Cancer
·
2
Trastuzumab-deruxtecan (T-DXd) nel carcinoma mammario metastatico HER2+: efficacia, gestione clinica e prospettive
2026
·
Fabio Canino
, Mario Giuliano
, et al.
·
Recenti Progressi in Medicina
·
1
PDF
359P Attrition rate and clinical benefit across treatment lines in metastatic breast cancer: Data from real-world population
2025
·
L. Belluzzi
, S. Natalizio
, et al.
·
ESMO Open
·
1
Prognostic role of HER2 expression in patients with ER-positive/HER2-negative breast cancer: Results from a population-based cancer registry study.
2023
·
Antonino Musolino
, Olga Serra
, et al.
·
Journal of Clinical Oncology
·
1
PDF
Correction: Incorporating weekly carboplatin in anthracycline and paclitaxel-containing neoadjuvant chemotherapy for triple-negative breast cancer: propensity-score matching analysis and TIL evaluation
2022
·
Maria Vittoria Dieci
, Luisa Carbognin
, et al.
·
British Journal of Cancer
·
1
PDF
Atezolizumab-Related Sarcoidosis-Like Reaction in Early Breast Cancer Patient: Know It To Diagnose It: A Case Report with Review of the Literature
2022
·
Antonio Tornincasa
, Fabio Canino
, et al.
·
Archives of Clinical and Medical Case Reports
·
1
Palbociclib in a patient with HR+/HER2- advanced breast cancer and HIV1 infection: a case report
2021
·
Fabio Canino
, Luca Moscetti
, et al.
·
Breast Cancer Management
·
1
Abstract PS5-05-30: Cycline Dipendent Kinase inhibitors 4/6 and endocrine therapy in the first line of treatment for HR+Her2- advanced breast cancer: a meta-analysis of the published real-world studies
2026
·
L. Moscetti
, I. Sperduti
, et al.
·
Clinical Cancer Research
Impact of Ethnicity on Breast Cancer Outcome: A Systematic Review and Meta-Analysis of Randomized Phase III Trials of the Last Decade
2025
·
Emma Zattarin
, Luca Moscetti
, et al.
·
JCO Global Oncology
443P Vaginal erbium laser for the treatment of genitourinary syndrome in premenopausal breast cancer patients
2025
·
S. Zaniboni
, O. Ponzoni
, et al.
·
ESMO Open
118P Mutational and clinical profile comparison between long and poor responders to first-line CDK 4/6 inhibitors
2025
·
B. Medici
, A. Farina
, et al.
·
ESMO Open
PDF
208P Clinicopathological factors and treatment management in HER2+ breast cancer patients with central nervous system metastasis
2024
·
O. Ponzoni
, G. Antonelli
, et al.
·
ESMO Open
PDF
Show more works
View as search
Works count:
39
Citation count:
231
H-index:
8
I10-index:
7
Year
Topic
Type